These results suggest that although DAS-IAP degrades the BCR-ABL protein, the inhibition of BCR-ABL kinase activity is more apparently involved in the inhibition of kinase signaling and CML cell growth under continuous exposure to the drug. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.